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Abstract
Purpose of Review Recognition of the importance of enthesitis as the pivotal pathological process underpinning
spondyloarthropathies (SpA) has increased in recent years. Thus, we summarized the current knowledge on the pathogenic role
of enthesitis on SpA shown by both animal models and human studies in vivo.
Recent Findings Experimental models have shown several SpA-like diseases that commence at entheses and are linked to nail
disease as well as dactylitis, two important entheseal-associated conditions in humans. Frequently, enthesitis is not the primary
outcome measure in studies of peripheral PsA and SpA although arguably it is the key parameter being indirectly assessed in
spinal disease in ankylosing spondylitis. The use of different agents including JAK, IL-17, and IL-23 inhibitors contributes
significantly to our understanding of enthesitis in terms of involved immune pathways.
Summary Enthesitis and enthesis organ inflammation may be the primary pathological process underlying SpA associated skeletal
inflammation. Emergent studies are beginning to elucidate the molecular basis for this type of joint inflammatory response.
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Introduction
In the last decades, great advances have occurred in the
etiopathogenetic understanding of the spondyloarthropathies
(SpA) which was paralleled by the introduction of the TNFi
therapies resulted in better clinical outcomes. A pivotal com-
ponent of these advances was the recognition that enthesitis,
defined as inflammation of tendon, ligament, and joint capsule
insertions to the bones, is the cardinal pathological process in
the SpA group of diseases [1, 2]. In this article, we focus on
recent aspects of enthesis biology in experimental studies and
in man and update the reader on new therapy developments
for enthesitis.
Enthesis Microanatomy
The enthesis organ, defined as a group of tissues including
fibrocartilages, bursa, fat pad, adjacent trabecular bone net-
works, deeper fascia, and enthesis, functions collectively to
carry out a common task, namely anchorage and stress resis-
tance [3, 4]. The recognition that the enthesis is an organ helps
to conceptualize why entheseal inflammation may be associ-
ated with diffuse extracapsular swelling in addition to synovi-
tis and osteitis. An especially important component of the
enthesis organ is the synovio-entheseal complex where bursal
and other synovial cavity resident macrophages provide lubri-
cation, nourishment, and metabolic requirements as well as
micro-debris waste disposal in health [5]. However, these res-
ident macrophages have also been suggested to trigger severe
joint swelling in disease [3, 6–8]. The functional anatomy of
the enthesis and how fibrocartilage-lined joints, some of
which wrap around tendons, function like entheses and the
unifying mechanical explanation for disease that stems from
these concepts has been well covered previously [4, 6]. Given
the fact that both the nail and the flexor tendons are respec-
tively anchored to the skeleton via the distal interphalangeal
joint tendon or accessory pulleys, creating an enthesis-like
structure provides further support for the key importance of
the enthesis in SpA-related skin and joint manifestations [9].
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The Primacy of Enthesitis in Animal Models
Recently, several animal model studies have demonstrated the
essential role of enthesitis in pathogenesis of the SpA group of
diseases [10] and shed light on the importance of specific
inflammatory pathways and various cytokines in acting local-
ly such as IL-23 [8], IL-17, and IL-22 as key pro-
inflammatory cytokine in SpA potentially secreted by
entheseal resident cells [8, 11]. Indeed, as result of better un-
derstanding of the immune pathways involved in enthesitis,
we are witnessing novel treatment advances that offer new
opportunities to improve clinical entheseal disease including
IL-23 and IL-17 blockers as biological agents, and small mol-
ecules such as PDE4 inhibitors and JAK inhibition [12–14].
However, the basis for the reported PDE4 inhibition effi-
cacy for enthesitis, but not synovitis in RA, is not understood
at this time.
In the last few years, several experimental animal models
of SpA-like disease have helped elucidate the role of enthesitis
as the primary pathological process in SpA, identifying vari-
ous entheseal T cell subtypes and new immune pathways
(Table 1). Systemic overexpression of IL-23 using hydrody-
namic injection of IL-23 minicircle DNA activated IL-23R+,
ROR-γt+ CD3+ CD4− CD8−, stem cell antigen 1 (Sca1)+
entheseal resident T cell lymphocytes inducing the transcript
expression of IL-6, IL-17, and IL-22 as well as of CXCL1
genes [8]. The same technology induced arthritis and
osteoblast-mediated bone remodeling and resulted in SpA-
like bone formation manifestation of SpAwith IL-22 but not
IL-17ADNAminicircles [8]. However, in the aforementioned
model, enthesitis was IL-17A dependent and this is consistent
with the SKG mouse model of enthesitis [8, 15].
In 2016, it was shown that the majority of IL-23R-
responsive cells in the normal murine entheses were γδ Tcells
expressing the RAR-related orphan receptor γt (ROR-γt)
transcription factor, as well as the IL-23 and CCR6 receptors,
and are capable of IL-17A production [16]. More specifically,
Reinhardt et al. analyzed entheseal lymphocytes fromC57BL/
6, Tcrd-H2BeGFP, Rorc-GFP, and IL-23R-eGFP murine
models, after performing hydrodynamic injection of IL-23
minicircle DNA [16]. Activated Vγ6+CD27− γ/δ Tcells con-
stituted the largest Tcell subset [16]. Of particular relevance to
the SpA concept was γδ T cells in the murine ciliary body,
thus offering a micro anatomical and immunological link be-
tween the enthesis and the eye [17].
TNF plays a key role in the pathogenesis of IBD, in which
enthesitis is also a typical manifestation when the disease also
involves extra-intestinal structures [18]. Another animal mod-
el demonstrating the involvement of entheses is the TNF over-
expression model that was reported by Armaka et al. [19] who
used a TNF transgenic model known as the TNFΔARE/+ mu-
tant mice, characterized by the development of Crohn’s-like
IBD and SpA-like disease [20]. Bone marrow-grafting
experiments showed that development of arthritis was depen-
dent on TNF receptor I (TNFRI) expression [21]. Indeed, it
was shown that TNFRI expression in mesenchymal cells re-
sulted in a SpA and intestinal phenotype, demonstrating that
mesenchymal cells are primary targets in this model [19]. A
confirmation of these findings is well given in the study by
Milia et al. [22], who studied transgenic rats with high expres-
sion of HLA-B27 and human β (2)-microglobulin (B27TR),
randomly assigned to TNFi treatment. Early and late admin-
istration of anti-TNFα antibodies prevented and improved
inflammation and joint remodeling, respectively, preserving
the enthesis organization [22]. Interestingly, SMAD1/5/8 sig-
naling, a marker of bone remodeling, was not inhibited by late
anti-TNFα treatment [22]. These animal models kindled con-
siderable interest in the theory that enthesitis therapy might be
associated with irreversible new bone formation lesions fol-
lowing biological agent therapy. At the present time, the con-
sensus is that the earlier that biological therapy is used in man,
then the lower the likelihood of entheseal new bone formation
occurrence in the spine [23].
Furthermore, enthesitis, or more specifically synovio-
entheseal complex disease, has been reported as an early feature
of paw inflammation in mice with a myeloid cell-specific A20
(TNFα-induced protein 3) deficiency [24]. These mice are
characterized by high levels of inflammatory cytokines, leading
to consistent NF-κB activation and significant production of
TNF, IL-1, and IL-6 by macrophages [25]. Nevertheless, in
the myeloid A20 knockout mice, SpA-type arthropathy is inde-
pendent of TNF but dependent on IL-1 and IL-6 [25]. In the
early phase of arthritis of these mice, Achilles tendon region
swelling was noted, and hematoxylin-eosin staining showed
inflammation of the synovio-entheseal complex (SEC) [24].
Disease was blocked by the tofacitinib administration which
provided pre-clinical support for JAKi in PsA and SpA.
The importance of the IL-23/17 axis has been further sup-
ported by other experimental studies where disease also com-
mences at the enthesis and is associated with other SpA man-
ifestations including nail disease and dactylitis [15, 26, 27].
There is evidence for local IL-23 production in the gut [28]
and it has been proposed that systemic circulation of IL-23
could then trigger SpA at the entheses [8]. IL-23 activating
resident Tcells within the enthesis promotes inflammation and
bone remodeling mediated by IL-17 and osteoproliferation
mediated by IL-22 [29]. Thus far, there is little data on the
source of IL-23/17 axis cytokines driving human arthritis and
questions relating to whether IL-23 in particular is locally or
systemically produced remain to be elucidated.
Human Studies of the Enthesis
The description of an IL-23-responsive population of T cells
[8], alongwith the description of a group of cytokine-dependent
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innate lymphoid cells (ILCs) [30], led to a search for innate
immune cells at the normal human enthesis. We selected small
normal interspinous process entheses from donors with no sys-
temic inflammatory disease to explore the presence of type 3
ILC populations. [31••]. The small interspinous process
entheses have advantages over large attachment sites like the
Achilles tendon where thick juxta-articular fibrocartilaginous
tissue that is completely devoid of immune cells precludes im-
mune cell subset evaluation.We showed that the normal human
enthesis did indeed harbor a rare population of IL-23R-
expressing type 3 ILCs [31••]. We were also able to demon-
strate the presence of a comparatively abundant population of
γδ T cells. In health, entheseal cells were present in both the
enthesis soft tissue and the peri-entheseal bone [31••].
Furthermore, there was little evidence for expression of IL-
17A transcripts in health, but of note, the IL-23R+ type 3
ILCs expressed TNFα transcript [31••]. Following stimulation
of human entheseal tissue with IL-23 and IL-1β, we demon-
strated upregulation of IL-17A and evidence for upregulation of
IL-17F and IL-22 (Fig. 1). The inducible expression of IL-22
on these entheseal resident immunocytes and the recognition
that IL-22 drives human MSC osteogenesis [32•] fit into a
model whereby inflammation at the entheses may later drive
new bone formation (Fig. 1).
Evaluating Enthesitis
Unfortunately, in humans, enthesitis remains stubbornly diffi-
cult to assess [33]. The complete avascularity of entheses at
bone attachment sites and the low vessel density in adjacent
ligaments and tendons as well as the lack of adaptive hyper-
plasia that is normally seen in synovitis make assessment of
these sites particularly challenging [33]. Moreover, despite the
existence of various clinical measures for enthesitis, there is
no sound consensus concerning their validity in PsA, since
gold standard validation has not been performed. Therefore,
it is necessary to rely on imaging rather than clinical exam-
ination in order to detect non-accessible sites of entheses.
Indeed, numerous studies have shown that ultrasound (US)
could detect a subclinical enthesitis in PsA patients
[34–36].
Typically, enthesitis is associated with diffuse peri-
entheseal soft tissue edema on magnetic resonance imaging
(MRI) with this adjacent reaction being usually more conspic-
uous than inflammation within the insertion which reflects the
greater vascularity of the peri-entheseal tissues (Fig. 2). Both
entheses and sacroiliac fibrocartilaginous joints have promi-
nent fibrocartilages and disease of both structures may be
associated with an adjacent severe osteitis that likely reflects
Table 1 Selected murine enthesitis models
Reference Species Strain Intervention Characteristics
Reihardt et al. [16] Mice Tcrd-H2BeGFP mice crossed
with mice of the susceptible
B10.RIII background
Hydrodynamic injection
of IL-23 minicircle DNA
Activated Vγ6+CD27− γ/δ T cells were
found in uninflamed entheseal tissue
and constituted the largest resident
T cell subset.
Armaka et al. [59•] Mice TNF-overexpressing mouse
model (TNFΔARE/+)
Spondyloarthritis with a CD-like pathology
localized primarily in the small intestine.
Additionally, the development of arthritis
was dependent on TNF receptor I
(TNFRI) expression with mesenchymal
cells being primary responders.
De wilde et al. [24] Mice A20myelKO mice A20 knockout Enthesitis was found to be an early
inflammatory lesion in A20myelKO mice.
A20 negatively modulated STAT1-dependent
gene transcription in myeloid cells which
was JAK/STAT dependent.
Benham et al. [15] Mice BALB/c ZAP-70(W163C)-
mutant (SKG) mice
β-1,3-Glucan injected
intraperitoneally
In curdlan-treated SKG mice, arthritis, enthesitis,
and ileitis were IL-23 dependent. Enthesitis
was specifically dependent on IL-17A and
IL-22. IL-17Awas pathogenic, while IL-22
was protective against ileitis.
Sherlock et al. [8] Mice B10.RIII mice Immunization with type
II collagen
IL-23 is essential in enthesitis and acts on
previously unidentified IL-23 receptor
(IL-23R)+, RAR-related orphan receptor
gt (ROR-gt)+CD3+CD4–CD8–, stem cell
antigen 1 (Sca1)+ entheseal resident T cells
which led to the induction of IL-6, IL-17,
and IL-22 as well as of CXCL1 secretion
leading to osteoblast remodeling which is
characteristic of enthesitis.
Curr Rheumatol Rep (2018) 20: 41 Page 3 of 8 41
the excellent vascularity of the marrow (Fig. 3). However,
neither MRI nor US excludes the presence of enthesitis, and
the role of imaging remains controversial since the use of
power Doppler (PD) which is typical of RA-related synovitis
activity is generally much less conspicuous at insertions [37,
38]. Studies comparing clinical enthesitis with imaging
enthesitis in SpA show virtually no correlations [34].
Furthermore, where suspected pathology is seen, it is uncom-
mon to get tissue to confirm the diagnosis. Therefore, the
assessment criteria remain subjective. The exact histopatho-
logical basis for the subclinical entheseal abnormalities pres-
ent in PsA and other forms of SpA is poorly understood.
However, a recent US study reported in abstract form has
shown that subclinical enthesopathy in psoriasis cases re-
gresses following anti-IL-12/23 therapy, suggesting an inflam-
matory component [39].
Among the diverse clinical measures for enthesitis, the
Leeds Enthesitis Index (LEI) uses the medial collateral liga-
ment (MCL) origin in both knees as a site of enthesitis [40].
This anatomic structure forms an elaborate synovio-entheseal
complex that might be inflamed as a result of events taking
place elsewhere within the synovial cavity; thus, it is hard to
interpret exactly what tenderness at this location means and
whether it could be linked to synovitis. It might be that these
difficulties and complexities in recognizing and measuring
enthesitis contributed to the GRAPPA-OMERACT for PsA
standardization unwittingly dropped enthesitis from core
domain assessments [41]. The move towards trials in early
PsA makes the need to address enthesitis an urgent one
since early disease may might be strongly linked.
Recent Clinical Developments
The response of human enthesitis to various therapeutic agents
goes some way to improve the rudimentary state of
immunological knowledge about human enthesis and the di-
verse immune pathways that are involved in disease [42].
Moreover, the use of enthesitis as an important manifestation
of PsA, and its evaluation in drug trials, and clinical practice as
well, has increased dramatically with enthesitis now a univer-
sal secondary outcome measure in trials [43]. The treatment of
enthesitis remains a challenge. Conventional DMARDs such
Fig. 1 Lymphocyte populations
defined at the human enthesis.
Thus far, two lymphocyte
populations have been defined at
the human enthesis. Innate
lymphoid cells are part of the IL-
23-responsive T cells which are
residents of the healthy enthesis.
Gamma delta T cells are also
resident at the enthesis. The
activation of resident T cells
within the enthesis by IL-23 may
promote inflammation,
osteogenesis, and bone loss and
remodeling. These lymphocyte
populations may release different
cytokines including IL-17 and IL-
22 and TNF-α
Fig. 2 Magnetic resonance imaging (MRI) of the sacroiliac joints (SIJ)
showing bilateral ischial tuberosity enthesitis in a patient with newonset
PsA. The site of soft tissue entheseal inflammation is depicted by
arrowheads. In this case, there is sparing of the bony attachment.
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as sulfasalazine and methotrexate are not significantly effective
for enthesitis management, yet NSAIDs remain the first-line ther-
apy [43] although corticosteroid therapy including injection,
where appropriate or feasible, is also an option. TNF blockade
is the standard of care for enthesitis and severe axial disease in
those patients with partial response to conventional DMARDs
[44]. However, in recent years, many efforts were made to assess
the efficacy of several therapeutic agents in enthesitis.
Recent phase 3 studies have shown efficacy of PDE4
blockers for PsA but with lower ACR 20 responses compared
to the biologic class of drugs. A favorable effect of the PDE4
blocker, apremilast, on enthesitis has been reported [45, 46].
Given that the PDE4 blockers are ineffective in RA and do not
block autoantibody production but suppress the neutrophil
influx to sites of tissue inflammation [47], it is likely that these
agents are working predominantly on innate immunity. This
supports the idea of what we termed MHC-1-opathy [48],
whereby in the SpA group of diseases, initial site-specific
innate immune activation drives adaptive immune activation
via CD8+ T cells, which in turn drive IL-17-related neutro-
philic tissue inflammation exacerbation of these diseases [48].
Two recent studies have evaluated Janus kinase (JAK) inhibi-
tion with tofacitinib, a pan JAK inhibitor for the treatment of
PsA [49•, 50]. In biologic naïve cases, tofacitinib was com-
pared to adalimumab, where enthesitis was assessed as a sec-
ondary outcome, reporting a favorable response [50].
However, in the second study, the pre-specified statistical hi-
erarchical model used precluded an evaluation of enthesitis
[49•]. It is likely that JAK inhibition will represent a new
option in the treatment of PsA and enthesitis. The precise
mechanism of action of JAK inhibition is unclear since over
50 different cytokines including interleukins, CSFs, and hor-
mones that share various signaling pathways are mediated by
JAKs [51••].
However, the two biggest classes of drugs used to treat PsA
and AS, namely TNF and IL-17 inhibitors, do not signal di-
rectly through the JAK pathway [52]. Nevertheless, IL-23
signals via tyrosine kinase 2 (Tyk2) blockers for psoriasis
support the idea of a therapy effect via IL-23 alone [51••, 53].
An unexpected finding in this field is the apparent non-
efficacy for ustekinumab for spinal enthesitis of AS despite
its efficacy in the peripheral skeleton (data not published). The
most obvious avenues for exploration are that the immune
system at the immunobiology peripheral and axial entheses
may be fundamentally different and that higher doses of
anti-IL-23 pathway cytokine are needed for axial disease.
One obvious difference is the relative absence of the
synovio-entheseal complex in the spine and where pathology
is often located at entheseal bone anchorage points [33].
However, this intriguing observation around IL-12/23 block-
ade apparent non-efficacy awaits further study including data
on the IL-23 pathway antagonism with specific p19 blockers.
The IL-17 blockers have also been evaluated for their effect
on enthesitis. Secukinumab a IL-17A blocker has shown effi-
cacy for enthesitis in several trials [54, 55]. Ixekizumab, a
second IL-17A blocker with a 50-fold higher affinity, showed
efficacy for enthesitis in the P-SPIRIT-1 study [56]. However,
in the P-SPIRIT 2 study with the same molecule in PsA cases
that failed to respond to prior TNF blockade, there was no
significant effect on enthesitis at the pre-specified 24-week
assessment, but there was evidence for efficacy at earlier time
points [57]. A third molecule, brodalumab, an IL-17RA
blocker, was also evaluated for its effect on enthesitis and no
significant effect was found in those patients who had scores
of more than 0 for enthesitis at week 12 between the group
receiving 140 mg of brodalumab and the group receiving
280 mg of brodalumab, as compared with the placebo group
[58]. However, although not statistically significant, there was
Fig. 3 Magnetic resonance
imaging (MRI) of the sacroiliac
joints (SIJ) showing bilateral
sacral joint bone marrow edema
on in a patient with early psoriatic
arthritis. The Bonemarrow edema
is more florid at the anterior part
of the joint adjacent to the
capsular enthesis. It remains to be
determined whether the patterns
of inflammation at entheses in
soft tissue or in the bone may
influence responses to therapy
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a greater numerical improvement in enthesitis in subjects on
higher dose of brodalumab. Given all the genetic and patho-
logical data and the existing studies, it seems that these agents
will be effective for the therapy of enthesitis.
Conclusions
Enthesitis is much more than local inflammation; indeed, it is
considered as the primary pathological process underling
SpA. This has been shown by investigating the enthesis in
both animal models and human studies in vivo. Enthesitis
management is still a challenging matter for rheumatologists
and various new agents were evaluated for their effect on
enthesitis reporting different findings. The use of different
agents including JAK, IL-17, and IL-23 inhibitors have con-
tributed significantly to our understanding of enthesitis in
terms of involved immune pathways. Nevertheless, there is
an unmet need for further studies to improve our understand-
ing about enthesopathy seeking a better detection, and there-
fore management.
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